Toni Choueiri, MD· @DrChoueiri · X·· 3 天前评分70
正文 · 原文
Post-IO RCC update by @DrDanielHeng in LITESPARK-011 Ph.III:
Bel/Len vs Cabo maintained PFS benefit (14.8 vs 10.8 mo; HR 0.74).
ORR 53% vs 40%; DOR 22 vs 12 mo.
OS favored Bel/Len (33.7 vs 28.6 mo; HR 0.85) but missed significance boundary.
#ESMO26 #RCC @myESMO @OncoAlert
198 浏览 · 6 赞 · 5 转发 · 0 回复
来源：Toni Choueiri, MD · x.com